Immunology of transplantation

Prevention and suppression of rejection after an organ transplant

A healthcare professional walking down a hallway with a patient in a hospital setting.
A healthcare professional walking down a hallway with a patient in a hospital setting.

Enhancing outcomes for transplant patients 

For more than 30 years, Astellas has been dedicated to empowering transplant specialists with evidence-based solutions that optimize care and drive positive outcomes at every stage of the transplant journey.

Organ transplantation goes beyond survival; it aims to restore recipients’ health to pre-illness levels, enabling a significantly improved quality of life.1

globe-icon

For patients with end-stage organ failure, transplantation is a life-saving procedure, with over 157,000 solid organ transplants performed globally in 2022.2, 3, 4, 5, 6

heart-icon

Optimizing the short-term survival and prolonging long-term survival and sustained functionality of each graft is essential for individual patients and society in general. With organ shortages and lengthy waiting lists, achieving sustainable survival outcomes benefits both patients and the broader healthcare system.7, 8, 9, 10

An Astellas scientist in a lab writing down data points on a clipboard related to her research assignment.

Advancing transplantation medicine

We take pride in being recognized as a trusted partner in transplantation science and medicine and are committed to advancing the field through ongoing research and development. Our focus is ensuring that patients have access to therapies that prioritize their health and well-being at every stage of their transplant journey.

An Astellas scientist in a lab writing down data points on a clipboard related to her research assignment.
Astellas employee shakes hands with a partner, symbolizing collaboration with professional organizations and patient groups to advance care for transplant patients worldwide.

Strong alliances

Collaboration with professional organizations and patient groups is central to our mission of advancing care and fostering innovation for transplant patients worldwide. Through these partnerships, we are making a meaningful difference by giving transplant patients a second chance at life.

Keep exploring

Astellas scientist looking into a microscope at one of the labs.

Research and development 

Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more about our R&D approach.

Family members laughing and smiling at the dinner table, one being a patient that recently went through a successful organ transplant.

Patient centricity

We support the development of innovative health solutions through a deep understanding of the patient experience, real-world evidence, medical needs and behavioral drivers of care. Learn more about how we are mobilizing teams across Astellas to improve patient outcomes.

Healthcare professionals walking down a hospital setting hallway together and talking.

Healthcare professionals

We invite healthcare professionals to visit our HCP portal, where you will find valuable information and resources that reflect our commitment to collaboration and addressing unmet medical needs.

1Burra P, De Bona M, Germani G et al. The Concept of Quality of Life in Organ Transplantation Transplantation Proceedings, 39, 2285–2287 (2007).

 

2Global Observatory on Donation and Transplantation. Available: http://www.transplant-observatory.org/data-charts-and-tables/chart/; Accessed 14 August 2023.

 

3Terrault NA, Francoz C, Berenguer M, Charlton M, Heimbach J. Liver Transplantation 2023: Status Report, Current and Future Challenges. Clin Gastroenterol Hepatol. 2023 Jul;21(8):2150-2166. doi: 10.1016/j.cgh.2023.04.005. Epub 2023 Apr 20. PMID: 37084928.

 

4Black CK, Termanini KM, Aguirre O, Hawksworth JS, Sosin M. Solid organ transplantation in the 21st century. Ann Transl Med. 2018 Oct;6(20):409. doi: 10.21037/atm.2018.09.68. PMID: 30498736; PMCID: PMC6230860.

 

5Vanholder et al. Organ donation and transplantation: a multistakeholder call to action. Nat Rev Nephrol 17, 554–568 (2021). https://doi.org/10.1038/s41581-021-00425-3.

 

6NICE, Immunosuppressive therapy for kidney transplant in adults. Technology appraisal guidance TA481. Published: 11 October 2017. https://www.nice.org.uk/guidance/ta481/resources/immunosuppressive-therapy-for-kidney-transplant-in-adults-pdf-82605021450181 Last accessed December 2024.

 

7NHS Blood and Transplant. Organ Specific Reports. 2021-22. Available at: https://www.odt.nhs.uk/statistics-and-reports/organ-specific-reports/ Last accessed December 2024.

 

8Etheredge et al. Assessing Global Organ Donation Policies: Opt-In vs Opt-Out. Risk Manag Healthc Policy. 2021 May 13;14:1985-1998. doi: 10.2147/RMHP.S270234

 

9The Council Of Europe European Committee On Organ Transplantation, Newsletter Transplant 2018. Available at: https://www.europarl.europa.eu/EPRS/Newsletter_Transplant_2019.pdf Last accessed December 2024.

 

10Lim MA, Bloom RD. How to maximize graft survival. Curr Opin Organ Transplant. 2023 Feb 1;28(1):55-63. doi: 10.1097/MOT.0000000000001039.